Podcast

Pagel Unpacks the Utility of PI3K Inhibitors in Lymphoid Malignancies

Author(s):

Dr. Pagel discusses the advances that have been made with PI3K inhibitors in lymphoid malignancies, the impact of the FDA approval of umbralisib on the treatment paradigm in follicular lymphoma and marginal zone lymphoma, and ongoing research poised to expand the armamentarium.

Welcome to OncLive On AirTM! I’m your host today, Jessica Hergert.

OncLive On AirTM is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director of the Hematopoietic Cell Transplantation Program at Swedish Cancer Institute, to discuss the evolution of PI3K inhibitors in lymphoid malignancies in light of the recent regulatory approval of umbralisib (Ukoniq) for patients with relapsed/refractory marginal zone lymphoma and follicular lymphoma.

In our exclusive interview, Pagel discussed the advances that have been made with PI3K inhibitors in lymphoid malignancies, the impact of the FDA approval of umbralisib on the treatment paradigm in follicular lymphoma and marginal zone lymphoma, and ongoing research poised to expand the armamentarium.

Related Videos
Francine Foss, MD
David C. Fisher, MD
Farrukh Awan, MD
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss long-term data for CPX-351 in acute myeloid leukemia.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss factors to help determine intensive chemotherapy fitness in acute myeloid leukemia.